How are our projects
selected?

The projects focus on issues such as:

  • Optimising healthcare pathways by analysing therapeutic treatment sequences to target and address disruption points,
  • Personalised medicine through the ability to identify markers for sub-populations which might benefit from a specific treatment,
  • Pharmaco-economics as a means of collectively enjoying improved efficiency.

The projects focus on rare, frequent, poor prognosis and paediatric cancers. With regard to the issues explored by each individual project, they address any public and/or private data available in France (medico-administrative, clinical, real-life, genomic data, etc.).

To validate each project submitted by the Association, the Board of Directors assesses the following weighted criteria:

The Cancer Data Platform being built by INCa is a first possible basis for analysis.

Initiated in 2010, its purpose is to collect and process data on persons at risk of or diagnosed with cancer. It draws upon on data from the French National Health Data System (SNDS), progressively supplemented by other information, such as that from surveillance and observation structures (cancer registries) and regional screening coordination centres.

Information from clinical practices, in particular from the oncology communication file, will also be integrated. Links will also be possible with past clinical trials, clinical and biological databases, biomaterial libraries or tumour libraries and with cohorts including clinical, biological and omic information.